For older adults, the flu vaccine could look a little different this year.

Compared with standard flu shots, Moderna’s mFlusiva generates stronger, longer-lasting immunity and is more effective at ...

The approval of Moderna’s new flu vaccine comes months after the FDA faced backlash for refusing to review the shot.

The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season.

The approval of the vaccine, called mFLUSIVA, which is manufactured by Moderna, follows a series of blows to mRNA research ...

In light of low flu vaccination coverage, the American Academy of Pediatrics has released its recommendation for the ...

The Food and Drug Administration has approved a new flu vaccine made with the same mRNA technology that was used for the COVID-19 shots.

The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

Previously, the COVID-19 immunizations made by Pfizer and Moderna were the only mRNA vaccines on the market.

The FDA approved Moderna's mFlusiva in early August for people 50 and older. It is the first mRNA flu vaccine offered in the ...

The shot, made by Moderna, will be available for this year's upcoming flu season.

The US Food and Drug Administration on Wednesday approved the United States’ first mRNA-based flu vaccine for adults 50 and ...